Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 4, 2009, Pages 335-343

  Ryden, Anna ^a   Stechova, Katerina ^b   Durilova, Marianna ^b   Faresjö, Maria ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c JÖNKÖPING UNIVERSITY   (Sweden)

Author keywords

Chemokines; Cytokines; High risk children; T helper cells; T regulatory cells; Type 1 diabetes

Indexed keywords

AUTOANTIGEN; C PEPTIDE; CD45 ANTIGEN; CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHYTOHEMAGGLUTININ; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; GLUTAMATE DECARBOXYLASE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN MICROARRAY; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; TH1 CELL; TH2 CELL; TH3 CELL; BLOOD; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; CYTOLOGY; DISEASE COURSE; DISEASE PREDISPOSITION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LONGITUDINAL STUDY; METABOLISM; RISK FACTOR;

ADOLESCENT; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CHILD; CHILD, PRESCHOOL; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNE TOLERANCE; LONGITUDINAL STUDIES; MALE; RISK FACTORS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

EID: 69249202525     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.958     Document Type: Article

References (45)

1. von Boehmer H. Positive selection of lymphocytes. Cell 1994; 76: 219-228.
2. Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995; 16: 90-98.
3. Tisch R, Yang X-D, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366: 72-75.
4. Karlsson Faresjö M, Ernerudh E, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scand J Immunol 2004; 59: 517-526.
5. Harrison LC, de Aizpurua H, Loudovaris T, Campbell IL, Cebon JS, Tait BD, et al. Reactivity to human islets and fetal pig proislets by peripheral blood mononuclear cells from subjects with preclinical and clinical insulin-dependent diabetes. Diabetes 1991; 40: 1128-1133.
6. Hummel M, Durinovic Bello I, Ziegler AG. Relation between cellular and humoral immunity to islet cell antigens in type 1 diabetes. J Autoimmun 1996; 9: 427-430.
7. Ellis TM, Schatz DA, Ottendorfer EW, Lan MS, Wasserfall C, Salisbury PJ, et al. The relationship between humoral and cellular immunity to IA-2 in IDDM. Diabetes 1998; 47: 566-569.
8. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314: 1360-1368.
9. Castano L, Eisenbarth GS. Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990; 8: 647-679.
10. Bradley LM, Asensio VC, Schioetz LK, Harbertson J, Krahl T, Patstone G, et al. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999; 162: 2511-2520.
11. Berman MA, Sandborg CI, Wang Z, Imfeld KL, Zaldivar FJ, Dadufalza V, et al. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol 1996; 157: 4690-4696.
12. Karlsson MGE, Sederholm Lawesson S, Ludvigsson J. Th1-like dominance in high-risk first-degree relatives of type 1 diabetic patients. Diabetologia 2000; 43: 742-749.
13. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated antibodies. Scand J Immunol 2001; 53: 510-513.
14. Roncarolo MG, Baccetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001; 182: 68-79.
15. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207-214.
16. Hussain MJ, Peakman M, Gallati H, Lo SSS, Hawa M, Viberti GC, et al. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 1996; 39: 60-69.
17. Kallmann BA, Hüther M, Tubes M, Feldkamp J, Bertrams J, Gries FA, et al. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes 1997; 46: 237-243.
18. Hedman M, Ludvigsson J, Karlsson Faresjö MGE. Nicotinamide reduces high secretion of IFN-γ in high-risk relatives even though it does not prevent type 1 diabetes. J Interferon Cytokine Res 2006; 26: 207-213.
19. Karlsson Faresjö M, Vaarala O, Thuswaldner S, Ilonen J, Hinkkanen A, Ludvigsson J. Diminished IFN-γ response to disease-associated autoantigens in children at diagnosis and during follow up of type 1 diabetes. Diabetes Metab Res Rev 2006; 22: 462-470.
20. Group, E.N.D.I.S.E. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trail of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925-931.
21. Karlsson MGE, Garcia J, Ludvigsson J. Cow's milk proteins cause similar Th1- and Th2-like immune response in diabetic and healthy children. Diabetologia 2001; 44: 1140-1147.
22. Stechova K, Kolouskova S, Sumnik Z, Cinek O, Kverka M, Karlsson Faresjö M, et al. Anti-GAD65 reactive peripheral blood mononuclear cells in the pathogenesis of cystic fibrosis diabetes mellitus. Autoimmunity 2005; 38: 319-323.
23. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975; 11: 541-548.
24. Ludvigsson J, Heding LG. C-peptide in children with juvenile diabetes. A preliminary report. Diabetologia 1976; 12: 627-630.
25. Mayer AF, Rharbaoui C, Thivolet J, Orgiazzi J, Madec AM. The relationship between peripheral T cell reactivity to insulin, clinical remissions and cytokine production in type 1 (insulin-dependent) diabetes mellitus. J Endocrinol Metab 1999; 84: 2419-2424.
26. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 1: 131-140.
27. Lohmann T, Laue S, Nietzschmann U, Kapellen TM, Lehmann I, Schroeder S, et al. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes 2002; 51: 2474-2480.
28. Avanzini MA, Ciardelli L, Lenta E, Castellazzi AM, Marconi M, Derosa G, et al. IFN-γ low production capacity in type 1 diabetes mellitus patients at onset of disease. Exp Clin Endocrinol Diabetes 2005; 113: 313-317.
29. Karlsson Faresjö MGE, Ludvigsson J. Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes. Scand J Immunol 2005; 61: 173-179.
30. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183: 1561-1567.
31. Quinn A, McInerney B, Reich EP, Kim O, Jensen KP, Sercarz EE. Regulatory and effector CD4 T cells in nonobese diabetic mice recognize overlapping determinants on glutamic acid decarboxylase and use distinct V beta genes. J Immunol 2001; 166: 2982-2991.
32. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-1920.
33. Rubtsov YP, Rudensky AY. TGFβ signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007; 7: 443-453.
34. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 exprssion in naive human CD4 + FOXP3- T cells by T-cell receptor stimulation is transforming growth factor-b-dependent but does not confer a regulatory phenotype. Blood 2007; 110: 2983-2990.
35. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TIM. Defective suppressor function in CD4 + CD25+ T-cells from patients with type 1 diabetes. Diabetes 2005; 54: 92-99.
36. Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik DL. IL-1β and IFN-γ induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 2003; 46: 255-266.
37. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 2001; 44: 325-332.
38. Reddy S, Bai Y, Robinson E, Ross J. Immunolocalization of monocyte chemoattractant protein-1 in islets of NOD mice during cyclophosphamide administration. Ann N Y Acad Sci 2006; 1079: 103-108.
39. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2008; 356: 1517-1526.
40. Krishnamurthy B, Mariana L, Gellert SA, Colman PG, Harrison LC, lew AM, et al. Autoimmunity to both proinsulin and IGRP is required for diabetes in nonobese diabetic 8.3 TCR transgenic mice. J Immunol 2008; 180: 4458-4464.
41. Keymeulen B, Vandemeulebroucke E, Ziegler AG, mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
42. Vaitaitis G, Wagner DH. High distribution of CD40 and TRAF2 in TH40 T cells rafts leads to preferential survival of this auto-aggressive population in autoimmunity. PLoS ONE 2008; 3: e2076.
43. Klein D, Timoneri F, Ichii H, Ricordi C, Pastori RL. CD40 activation in human pancreatic islets and ductal cells. Diabetologia 2008; 51: 1853-1861.
44. Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116: 1371-1381.
45. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial. Lancet 2001; 358: 1749-1753.